- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07345910
Miljø, patogener og vertsinteraksjoner ved melioidos (DeEPH)
Avkoding av triaden: samspillet mellom miljø, patogen og vert i melioidose (DeEPH)
This is a longitudinal, multicentre observational study conducted across three established microbiology units integrated within hospital and community health systems in Thailand, Lao PDR, and Cambodia.
The hospital cohort will enroll approximately1,000 patients with positive melioidosis. Participants will be followed at six time points from admission through one year (post-discharge) to capture acute and recovery-phase outcomes, with clinical data collected on demographics, comorbidities, exposures, treatment, adherence, and outcomes.
For each confirmed case, a healthy control will be recruited within two weeks and matched by age, sex, and village of residence. Controls with no symptoms or history of melioidosis will provide a single blood sample at enrolment and will be followed by telephone at 6 and 12 months.
In addition to hospital-based surveillance, a high-risk community in northern Ubon Ratchathani-referred to as the Sandbox Village-will be intensively monitored to capture subclinical infections and to assess environmental factors influencing disease acquisition.
This study is funded by the Wellcome Trust. The grant reference number is 323077/Z/24/Z
Studieoversikt
Status
Forhold
Detaljert beskrivelse
This is a longitudinal, multicentre observational study conducted across three established microbiology units integrated within hospital and community health systems:
- Sunpasitthiprasong Hospital, Ubon Ratchathani, Thailand (MORU);
- Mahosot Hospital, Vientiane, Lao PDR (LOMWRU); and
- Angkor Hospital for Children, Siem Reap, Cambodia (COMRU).
In addition to hospital-based surveillance, a high-risk community in northern Ubon Ratchathani-referred to as the Sandbox Village-will be intensively monitored to capture subclinical infections and to assess environmental factors influencing disease acquisition.
Participant Recruitment and Follow-up
Hospital cohort:
Patients with melioidosis will be recruited at all three hospital sites. The study plans to recruit 1,000 patients, who will be followed longitudinally at six time points: Day 0 (admission), Days 3 and 7 (acute phase), and Days 30, 180, and 365 (recovery phase).
Clinical data collected will include demographic characteristics, underlying comorbidities, environmental exposures, lifestyle and behavioural factors, treatment history, patient-reported medication adherence, and follow-up outcomes.
Healthy controls:
Each patient will be matched with a healthy control recruited within two weeks of diagnosis, based on age, sex, and village of residence. Controls will have no current symptoms or prior history of melioidosis. They will provide a single blood sample at enrolment for DNA extraction and antibody profiling and will be followed up by telephone on Days 180 and 365.
Community cohort:
To complement hospital-based data and to identify subclinical infections, intensive community surveillance will be conducted in the Sandbox Village, a high-incidence area within the Ubon Ratchathani region. All residents (approximately 400 individuals) will be enrolled. DNA samples will be collected at baseline, and serum samples will be obtained every two months over a 42-month period, either at participants' homes or at a central village location, to measure antibody responses to Burkholderia pseudomallei as a proxy for exposure.
Community cohort:
To complement hospital-based data and to identify subclinical infections, intensive community surveillance will be conducted in the Sandbox Village, a high-incidence area within the Ubon Ratchathani region. All residents (approximately 400 individuals) will be enrolled. DNA samples will be collected at baseline, and serum samples will be obtained every two months over a 42-month period, either at participants' homes or at a central village location, to measure antibody responses to Burkholderia pseudomallei as a proxy for exposure.
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Kamolchanok Claire Chewapreecha, PhD
- Telefonnummer: 662 203 6333
- E-post: claire@tropmedres.ac
Studiesteder
-
-
-
Siem Reap, Kambodsja
- Har ikke rekruttert ennå
- Cambodia-Oxford Medical Research Unit (COMRU)
-
Ta kontakt med:
- Paul Turner, MD
- E-post: Pault@tropmedres.ac
-
-
-
-
-
Vientiane, Laos
- Har ikke rekruttert ennå
- Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit (LOMWRU)
-
Ta kontakt med:
- Elizabeth Ashley, MD
- E-post: Elizabeth.Ashley@tropmedres.ac
-
-
-
-
-
Ubon Ratchathani, Thailand
- Rekruttering
- Sunpasitthiprosong Hospital
-
Ta kontakt med:
- Kamolchanok C Chewapreecha, PhD
- Telefonnummer: 022036333
- E-post: claire@tropmedres.ac
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Melioidosis patients:
Patients confirmed to have melioidosis.
Healthy controls:
For each confirmed melioidosis case, a healthy control-defined as having no current fever, no evidence of soft tissue infection, and no prior history of melioidosis-will be recruited from satellite blood bank donors within approximately two weeks of case identification. Controls will be matched by age (±5 years), sex, and village of residence.
Sandbox Village residents:
All residents of the Sandbox Village, a high-risk area for melioidosis, will be enrolled to monitor disease progression and to evaluate the impact of improved water sanitation.
Beskrivelse
Inclusion criteria for melioidosis patients:
- Age ≥20 years
- Positive for Burkholderia pseudomallei from any clinical samples
- Resident of the study area for at least two years, including the follow-up period
- Willing to participate and give informed consent.
Inclusion criteria for healthy controls:
- Age ≥20 years
- Currently healthy as judged by study doctor
- Resident of the study area for at least two years, including the follow-up period
- Willing to participate and give informed consent.
Inclusion criteria for sandbox residents:
- Age ≥20 years
- Resident of the study area for at least two years, including the follow-up period
- Willing to participate and give informed consent.
Exclusion criteria for melioidosis patients:
- Current tuberculosis (TB) or TB treatment within the past six months
- Documented HIV infection or use of immunosuppressive therapy in the past 12 months
Exclusion criteria for healthy controls:
- History of melioidosis
- Significant acute illness
- Current fever or soft tissue infection
Exclusion criteria for sandbox residents
-N/A
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
Melioidosis patients
Patients confirmed to have melioidosis |
|
Healthy controls
Healthy controls will be enrolled for each confirmed melioidosis case. A healthy control is defined as an individual with no current fever, no evidence of soft tissue infection, and no prior history of melioidosis. Controls will be recruited within approximately two weeks of case identification and will be matched to cases by age (±5 years), sex, and village of residence. |
|
Sandbox village cohort
All residents of the Sandbox Village, a high-risk area for melioidosis, will be enrolled to monitor disease progression and to evaluate the impact of improved water sanitation. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Utvikling av melioidos etter eksponering, vurdert blant melioidosetilfeller
Tidsramme: 365 dager
|
365 dager
|
|
Utvikling av melioidose etter eksponering, vurdert blant friske kontroller
Tidsramme: 365 dager
|
365 dager
|
|
Utvikling av melioidose etter eksponering, vurdert blant innbyggerne i Sandbox Village
Tidsramme: 3,5 år
|
3,5 år
|
|
Dødelighet i den akutte fasen av infeksjon blant personer med melioidose (melioidose-tilfeller).
Tidsramme: 365 dager
|
365 dager
|
|
Antall sykehusinnleggelser etter utskrivelse blant personer med melioidose (melioidose-tilfeller).
Tidsramme: 365 dager
|
365 dager
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Endringer i sykdomsutvikling etter eksponering knyttet til interaksjoner mellom miljømodifikasjoner.
Tidsramme: 3,5 år
|
3,5 år
|
|
Endringer i dødelighet under den akutte fasen av infeksjon etter eksponering assosiert med interaksjoner mellom miljømodifikasjoner.
Tidsramme: 365 dager
|
365 dager
|
|
Endringer i sykehusinnleggelse etter bedring assosiert med samspill mellom miljømessige modifikasjoner.
Tidsramme: 365 dager
|
365 dager
|
|
Endringer i sykdomsutvikling etter eksponering knyttet til interaksjoner mellom kliniske behandlingsfaktorer.
Tidsramme: 365 dager
|
365 dager
|
|
Endringer i dødelighet under den akutte fasen av infeksjon etter eksponering knyttet til interaksjoner mellom kliniske behandlingsfaktorer.
Tidsramme: 365 dager
|
365 dager
|
|
Endringer i sykehusinnleggelse etter utskrivelse knyttet til samspill mellom kliniske behandlingsfaktorer.
Tidsramme: 365 dager
|
365 dager
|
|
Endringer i sykdomsutvikling etter eksponering knyttet til interaksjoner som involverer genetisk mottakelighet.
Tidsramme: 365 dager
|
365 dager
|
|
Endringer i dødelighet i den akutte fasen av infeksjon etter eksponering forbundet med interaksjoner som involverer genetisk sårbarhet.
Tidsramme: 365 dager
|
365 dager
|
|
Endringer i sykehusinnleggelse etter bedring assosiert med interaksjoner som involverer genetisk sårbarhet.
Tidsramme: 365 dager
|
365 dager
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Kamolchanok Claire Chewapreecha, PhD, Mahidol Oxford Tropical Research Unit
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- MEL25001
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
The study outputs, including genomic and transcriptomic data and associated metadata, will be valuable for future research. In compliance with the Wellcome Trust's open data policies and to encourage reproducibility, data will be deposited in two repositories:
Human genomic and transcriptomic data: European Genome-Phenome Archive (EGA), under managed access
Bacterial genomic data: European Nucleotide Archive (ENA), open access
Pseudonymised metadata, including participant demographics and microbiological findings, will be shared with qualified researchers in accordance with the General Data Protection Regulation (GDPR). No personally identifiable information will be shared, and participants will not be identifiable from any released data.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .